Oncology News

ESMO oncology news ensures that you're always kept up to date with the latest developments that affect you and your daily practice. Make sure you check these pages frequently, or sign up to our newsletter.

Filter

Date Title Topic
28 Aug 2018 Molecular Insights in Clinical Responses to PD-1 Inhibition in Metastatic Gastric Cancer Gastrointestinal cancers - Cancer Immunology and Immunotherapy
27 Aug 2018 Withdrawal of Application for a Change to the EU Marketing Authorisation for Nivolumab Gastrointestinal cancers - Cancer Immunology and Immunotherapy
24 Aug 2018 EMA Recommends Extension of Indications for Epoetin Alfa (Abseamed, Binocrit and Epoetin alfa Hexal) Palliative and supportive care
23 Aug 2018 EMA Refuses a Change to the Marketing Authorisation for Blinatumomab Haematologic malignancies - Cancer Immunology and Immunotherapy
22 Aug 2018 EMA Opens Consultation on Biopharmaceutics Classification System Based Biowaivers Bioethics, legal and economic issues
21 Aug 2018 EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim Palliative and supportive care
20 Aug 2018 European Commission Consultation on Guidelines on Good Clinical Practice for Advanced Therapy Medicinal Products Bioethics, legal and economic issues
17 Aug 2018 Blood-based Tumour Mutational Burden Assay Predicts Clinical Benefit in NSCLC Patients Treated with Atezolizumab Lung and other thoracic tumours - Translational research - Cancer Immunology and Immunotherapy
16 Aug 2018 EMA Recommends Granting a Marketing Authorisation for Generic Lenalidomide Haematologic malignancies - Anticancer agents & Biologic therapy
14 Aug 2018 EMA Refuses a Change to the Marketing Authorisations for Nivolumab and Ipilimumab Genitourinary cancers - Cancer Immunology and Immunotherapy
13 Aug 2018 FDA Approves Mogamulizumab-kpkc for Mycosis Fungoides or Sézary Syndrome Haematologic malignancies - Cancer Immunology and Immunotherapy
10 Aug 2018 EMA Recommends Granting a Marketing Authorisation for Generic Gefitinib Lung and other thoracic tumours - Personalised medicine - Anticancer agents & Biologic therapy
09 Aug 2018 EMA Recommends Extension of Indications for Daratumumab Haematologic malignancies - Anticancer agents & Biologic therapy
08 Aug 2018 EMA Recommends Extension of Indications for Blinatumomab Haematologic malignancies - Cancer Immunology and Immunotherapy
07 Aug 2018 EMA Recommends Extension of Indications for Dabrafenib and Trametinib Melanoma and other skin tumours - Anticancer agents & Biologic therapy